The 3 autoimmune disorder biosimilars developed by Samsung Bioepis (Benepali, Imraldi, Flixabi) made slower sales in Europe in the first half of this year. Total sales fell by 4.7% compared to the previous year. Sales of the products had suffered a hard blow from the recent strong dollar and the continued pressure to cut prices.

According to the Biogen’s earnings call that was on the 21st (local time), the 3 biosimilars Benepali, Imraldi, and Flixabi made $388.2 million (₩510.1 billion) in sales in the period. This is a 4.7% drop YoY from the $407.5 million (₩535.5 billion) the products had made in the same period last year. Benepali’s sales dropped 5.2% to $230.5 million (₩302.9 bi